An Open-Label, Long-Term Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants with Erythropoietic Protoporphyria (EPP)
Latest Information Update: 19 Nov 2024
Price :
$35 *
At a glance
- Drugs Bitopertin (Primary)
- Indications Erythropoietic protoporphyria
- Focus Adverse reactions; Therapeutic Use
- Acronyms HELIOS
- Sponsors Disc Medicine
- 21 Feb 2024 Status changed from not yet recruiting to recruiting.
- 05 Sep 2023 Planned initiation date changed from 1 Jun 2023 to 1 Sep 2023.
- 05 Jun 2023 New trial record